bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer

Urology

Volumn 52, Issue 6, 1998, Pages 1085-1090

  MacKey, Timothy J ^a   Borkowski, Andrew ^a   Amin, Pradip ^a   Jacobs, Stephen C ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2;

AGED; APOPTOSIS; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIOSENSITIVITY; RETROSPECTIVE STUDY;

AGED; BCL-2-ASSOCIATED X PROTEIN; GENETIC MARKERS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 0032402183     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00360-4     Document Type: Article

References (33)

1. Wingo P.A., Tong T., Bolden S. Cancer statistics. CA Cancer J Clin. 45:1995;8-30.
2. Schellhammer P.F. Radiation therapy for localized prostate cancer what has been and still remains to be learned . Stamey T. Monographs in Urology. vol 15:1994;78-92 Medical Directions Publishing, Stanford California.
3. Sklar G.N., Eddy H.A., Jacobs S.C., et al. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells the role of apoptosis . J Urol. 150:1993;1526-1532.
4. Soldatenkov V.A., Prasad S., Notario V., et al. Radiation-induced apoptosis of Ewing's sarcoma cells DNA fragmentation and proteolysis of poly(ADP-ribose) polymerase . Cancer Res. 55:1995;4240-4242.
5. Meyn R.E., Stephens L.C., Mason K.A., et al. Radiation-induced apoptosis in normal and pre-neoplastic mammary glands in vivo significance of gland differentiation and p53 status . Int J Cancer. 65:1996;466-472.
6. Kyprianou N. Apoptosis therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer . World J Urol. 13:1994;299-303.
7. Kyprianou N., King E., Bradbury D., et al. bcl-2 overexpression delays radiation induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer. 70:1997;341-348.
8. Hockenbury D.M., Nunez G., Milliman C., et al. bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-336.
9. Reed J.C. bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
10. Weller M., Malipiero U., Aguzzi A., et al. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 95:1995;2633-2643.
11. McDonnell T.J., Troncoso P., Brisbay S.M., et al. Expression of the protooncogene bcl-2 in prostate and its association with emergence of androgen-independnet prostate cancer. Cancer Res. 52:1992;6940-6944.
12. Colombel M., Symmans F., Gil S., et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol. 143:1993;390-400.
13. Tu H., Jacobs S.C., Borkowski A., et al. Incidence of apoptosis and cell proliferation in prostate cancer relationship with TGF-β1 and bcl-2 expression . Int J Cancer. 69:1996;357-363.
14. Epperly M.W., Santucci M.A., Reed J.C., et al. Expression of the human bcl-2 transgene increases the radiation resistance of a hematopoietic progenitor cell line. Radiat Oncol Invest. 2:1994;77-83.
15. Oltavi Z.N., Milliman C.L., Korsmeyer S.J. bcl-2 heterodimerizes in vivo with a conserved homologue BAX that accelerates cell death. Cell. 74:1994;609-619.
16. Sakakura C., Sweeney E.A., Shirahama T., et al. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer. 67:1996;101-105.
17. Krajewska M., Krajewski S., Epstein J.I., et al. Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-1 expression in prostate cancers. Am J Pathol. 148:1996;1567-1576.
18. Casparini G., Barbareschi M., Doglioni C., et al. Expression of bcl-2 predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res. 1:1995;189-198.
19. Gallo O., Boddi V., Calzlari A., et al. Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin Cancer Res. 2:1996;261-267.
20. Zietman A.L., Tibbs M.K., Cohen J.J. Rigorous analysis for biochemical outcome following external beam therapy. J Urol. 153:1995;502A.
21. Dugan T.C., Shipley W.U., Young R.H. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate correlation with original histologic grade and current prostate specific antigen levels . J Urol. 146:1991;1313-1316.
22. Danella J., Steckel J., Dorey F. Detectable prostate specific antigen levels following radical prostatectomy relationship of doubling time to clinical outcome . J Urol. 152:1994;447A.
23. Campos L., Rouault J.P., Sabido O., et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091-3096.
24. Salomons G.S., Brady H.J.M., Verwwijs-Janssen M., et al. The bax:bcl-2 ratio modulates the response to dexamethasone in leukemic cells and is highly variable in childhood acute leukemia. Int J Cancer. 71:1997;959-965.
25. Chresta C.M., Masters J.R.W., Hichkman J.A. Hypersensitivity of human testicular tumors to etopiside induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Res. 56:1996;1834-1841.
26. Kitada S., Krajweski S., Miyashita T., et al. Gamma-irradiation induces upregulation of bax protein and apoptosis in radiosensitive cells in vivo. Oncogene. 12:1996;187-192.
27. Antonson B., Conti F., Ciavatta A., et al. Inhibition of bax channel-forming activity by bcl-2. Science. 277:1997;370-372.
28. Miyashita T., Reed J.C. Tumor supressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
29. Miyashita T., Reed J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
30. Prendergrast N.J., Atkins M.R., Schatte E.C., et al. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol. 155:1996;1685-1692.
31. Stattin P., Damber J.E., Modig H., et al. Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients. Int J Radiat Oncol Biol Phys. 35:1996;885-889.
32. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Conformal external beam treatment of prostate cancer. Urology. 50:1997;87-92.
33. Pisansky T.M., Kahn M.J., Rasp G.M., et al. A multiple prognostic index predictive of disease outcome following irradiation for clinically localized prostatic carcinoma. Cancer. 79:1997;337-344.